Can lenvatinib/lenvatinib be taken on and off for 21 days and 7 days?

Lenvatinib is an oral targeted anti-cancer drug commonly used to treat malignant tumors such as thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial cancer. When treating lenvatinib, a medication regimen suitable for the patient is usually developed based on the doctor's recommendations, including the schedule of medication and discontinuation times. Regarding the treatment method of using Lenvatinib 21 days on and 7 days off is still uncertain.

In studies of the treatment across various cancer types, lenvatinib prolonged progression-free survival (PFS) in some patients. PFS is the length of time a patient's cancer does not get worse during and after treatment compared with another treatment or a placebo (an inactive treatment).

The median treatment duration of lenvatinib in thyroid cancer studies was 16.1 months; the median progression-free life (PFS) was 18.3 months. LenvatinibThe median treatment duration in advanced renal cancer studies was 16.1 months; the median PFS in combination with everolimus was 14.6 months, in 49% of patients with unresectable hepatocellular carcinoma span>The median duration of treatment with lenvatinib was at least 6 months; the median overall survival was 13.6 months; in studies of patients with certain types of endometrial cancer, the median duration was 7 months but could be as long as 37.8 months. In 69% of patients with endometrial cancer, treatment responses lasted for at least 6 months.

Typically, patients will take lenvatinib until your body no longer responds to the drug or the side effects become severe and intolerable. In safety studies conducted by the manufacturer, most patients took lenvatinib for 16 months to treat various types of cancer.